BMS-Tempus, Roche-Zymeworks, and LGM-Sannova deals show what AI data, trispecifics, and nitrosamine testing mean for CMC, QA, and development teams.
News|Articles|September 2, 2003
- Pharmaceutical Technology-09-02-2003
- Volume 27
- Issue 9
CROs Hoping for Research Burst in Second Half of 2003
Author(s)Jim Miller
CROs and contract manufacturers had a decent second quarter, but they are hoping that Big Pharma comes through with a burst of trial start-ups in the second half of 2003.
Advertisement
Articles in this issue
about 23 years ago
September 2003about 23 years ago
In the Spotlight September 2003about 23 years ago
Counterfeiting, Compliance, and Controlsabout 23 years ago
September 2003about 23 years ago
Disposable Filtration Lightens Cleaning and Validation LoadAdvertisement
Related to this article
Jane Zhang of ETCH Sourcing explains why geopolitics, transparency, and partnership now weigh as heavily as cost and quality when companies choose suppliers, in this episode of Ask the Expert, moderated by Susan J. Schniepp of Nelson Labs.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Nitrosamine Problems and Industry Solutions: PharmTech Explained
2
AAPS PharmSci 360 2026: E&L Standards Harmonization
3
OpenAI Bets on Accelerating Drug Development Timelines With Orchestra Bio
4
Formulation and Evaluation of a Sustainable Analgesic Cream Utilizing Renewable Bio-Based Ingredients and Green Chemistry Design Principles
5